North America electronic drug delivery systems market is projected to register a CAGR of 8.4% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027
Market Segmentation:
North America Electronic Drug Delivery Systems Market By Type (Electronic Infusion Pumps, Electronic Injection Pens, Electronic Auto-Injectors, Electronic Inhalers, Electronic Capsules, Others), Component (Sensors, Wireless Communicator and Antennas, Micro Pumps and Flow Regulators, Drug Reservoir, Microcontroller, Others), Connectivity (Bluetooth Low Energy (BLE), Wi-Fi, Ethernet, NB-IoT, Others), System Type (Battery-Powered Systems, Rechargeable Systems), Application (Diabetes, Asthma and Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Growth Hormone Therapy, Immunodeficiency Disease, Cardiovascular Disease, Thalassemia, Others), End User (Home Healthcare, Hospitals, Clinics, Ambulatory Centers, Others), Country (U.S., Canada , Mexico)- Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the North America electronic drug delivery systems market are:

• Favorable reimbursement scenario
• Growing demand for biologics
Market Players:
The key market players for North America electronic drug delivery systems market are listed below:
• AstraZeneca
• Amgen Inc.
• Merck KGaA
• Bayer AG
• Nemera
• F. Hoffmann-La Roche Ltd
• Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.)
• AptarGroup, Inc.
• Novo Nordisk A/S.
• ViCentra B.V.
• Medtronic
• United Therapeutics Corporation
• Companion Medical
• Tandem Diabetes Care, Inc.
• Insulet Corporation
• BD
• B. Braun Melsungen AG
• West Pharmaceutical Services, Inc.